Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 36Magnetic Resonance Spectroscopy 23Gemcitabine 19Specimen Handling 15Nivolumab 12Carboplatin 12Surveys and Questionnaires 11Paclitaxel 11Cetuximab 11Early Intervention, Educational 10Bevacizumab 10Standard of Care 9Cyclophosphamide 9Cisplatin 9Radiosurgery 8Methods 8Fluorouracil 8Docetaxel 8Blood Specimen Collection 8Psychiatric Rehabilitation 7Pemetrexed 7sargramostim 6aldesleukin 6Taxes 6Injections 6Fluorodeoxyglucose F18 6Educational Status 6Drug Therapy 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × parsaclisib × Gastrointestinal × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡